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ABSTRACT
In contrast to lower eukaryotes, most vertebrate
cells are characterized by a moderate efficiency
of homologous recombination (HR) and limited
feasibility of targeted genetic modifications. As
a notable exception, the chicken DT40 B cell line
is distinguished by efficient homology-mediated
repair of DNA lesions during Ig gene conversion,
and also shows exceptionally high gene-targeting
efficiencies. The molecular basis of these
phenomena is elusive. Here we show that the
activity levels of Ubc13, the E2 enzyme responsible
for non-canonical K63-linked polyubiquitination, are
critical for high efficiency of Ig gene conversion and
gene targeting in DT40. Ubc13
+/  cells show sub-
stantially lower homology-mediated repair, yet do
not display changes in somatic hypermutation,
overall DNA repair or cell proliferation. Our results
suggest that modulation of the activity of K63-linked
polyubiquitination may be used to customize HR
efficiencies in vertebrate cells.
INTRODUCTION
Maintenance of genetic information is a fundamental
requirement for organismic survival. Accordingly, DNA
repair mechanisms are highly conserved, including
excision repair for removal of altered bases, mismatch
and post-replication repair for replication-associated
problems, and double-strand break repair for re-ligation
of breaks disrupting helix continuity (1). The latter
encompasses non-homologous end joining (NHEJ) and
homologous recombination (HR), which both restore
the helix but diﬀer with respect to ﬁdelity (2). For most
forms of DNA damage, several repair mechanisms act in a
redundant, cooperative or even competitive manner to
ensure optimum accuracy and eﬃciency of rectiﬁcation.
Despite this variety of DNA repair mechanisms, some
instances call for increased genetic variability. A
prototypic example is the vertebrate adaptive immune
system that relies on intricate genetic mechanisms to
generate a vast array of antigen receptors to ﬁght
invading pathogens (3). Initially, V(D)J-recombination
generates numerous patchwork sequences encoding
antigen receptors with diﬀerent speciﬁcity. For further
diversiﬁcation, B lymphocytes may introduce templated
or non-templated changes into these V(D)J joints by
immunoglobulin gene conversion (Ig GC) or somatic
hypermutation (SHM) (4,5). Both processes are initiated
via cytidine deamination by activation-induced deaminase
[AID (6)], which precipitates either HR with upstream
pseudogenes during Ig GC, or random mutagenesis
during SHM. The relative incidence of these two processes
diﬀers between species and may be determined by the
overall capacity of the cells to perform HR (7).
The DT40 cell line, derived from a chicken bursal B cell,
constitutively diversiﬁes its endogenous Ig light chain
genes by Ig GC (5). Probably as a side eﬀect, the cells
also display very high activity of HR, and the resultant
exceptional targeting eﬃciencies have made DT40 a
valuable tool to study vertebrate gene function. The
molecular basis for high HR activity in DT40 has
remained elusive. Indeed, complete inactivation of HR
has proven incompatible with DT40 survival (8).
Inactivation of non-essential HR factors impairs DNA
damage tolerance of the cells and leads to a shift from
Ig GC to SHM (7). A treatment that would selectively
aﬀect HR capacity of the cells without detrimental
eﬀects on other parameters has not been identiﬁed to date.
It is well recognized that HR avoids aberrant repair of
some DNA lesions. In case of DNA double-strand breaks,
HR is able to correctly restore even challenging lesions
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NHEJ is often error-free, but may also lead to deletions or
chromosomal translocations (2). In case of DNA changes
aﬀecting only one strand, such as bulky adducts or
abasic sites, homology-based error-free bypass may be
employed during replication to avoid mutagenic bypass
by translesion synthesis (9). The choice between these
options is regulated by the Rad6 pathway: monoubi-
quitination of proliferating cell nuclear antigen (PCNA)
by Rad6/Rad18 recruits translesion polymerases, and
K63-linked PCNA polyubiquitination by Ubc13/Mms2
is the basis for error-free bypass via homology-based
template switching to the undamaged sister chromatid
(10). Ubc13 also plays a critical role in HR, due to its
interaction with RNF8/RNF 168 and subsequent
ubiquitination events at sites of DNA damage (11,23).
In the present study, we have analysed the impact
of partial interference with Ubc13 function in DT40
cells. We show that Ubc13 heterozygosity selectively inter-
feres with Ig GC and gene targeting eﬃciency, without
aﬀecting the other parameters studied. Our ﬁndings
suggest that quantitative interference with K63-linked
ubiquitin conjugation, which plays a key role in HR
(8,11), may be used to ﬁne-tune the targeting capacity of
vertebrate cells.
MATERIALS AND METHODS
Cells, vectors and targeting
DT40Cre1 and DT40wV- cells were cultured as described
before (12). For construction of a Ubc13 targeting vector,
the left and right arms were ampliﬁed with 13Ub1, 13Ub2,
13Ub3 and 13Ub4 (for primer sequences, see Table 1), and
cloned into pBluescriptKS together with loxP-ﬂanked cas-
settes for puromycin or blasticidin resistance (13). For
reconstitution of Ubc13, its coding sequence was ampliﬁed
using 13Ub8 and 13Ub9, cloned into the pExpress vector,
and the resultant Ubc13 cassette was cloned into the Nhe1
site of ploxGPT (13).
Transfection of DT40 cells and screening for targeted
integration with the primers 13Ub101 and Pu4 or Bs1
were done as described (12). For Southern blots,
genomic DNA was cut with PstI and fragments were
detected with a probe ampliﬁed by the primers 13Ub201
and 13Ub202.
Assays for Ig GC and SHM
Analyses of Ig GC and SHM were done as before (12),
with the following exceptions: cells were cultured for 6
weeks after subcloning before FACS analysis for Ig GC,
and for 2 more weeks for sequencing of the Ig light chain
genes. For SHM analysis, cells were cultured for 14 days
after subcloning for FACS analysis and stained with
anti-chicken-IgM-PE (Southern Biotec, Birmingham,
Alabama). SHM sequence analyses were carried out
after 4 more weeks of culture.
Analysis of proliferation and cell survival
For analysis of cell proliferation, cells were labelled with
the Vybrant
TM CFDA SE Cell Tracer Kit (Invitrogen,
USA) and FACS analyses were performed every
10–12h. The sensitivity of the cells to DNA damaging
drugs was tested using a modiﬁed colony survival assay
according to a published protocol (14). Cells were treated
with the drugs in six well plates with 1 10
6 cells in 5ml
per well for 2h at 37 C. The cells were then washed twice
and resuspended in 10ml. One hundred microlitres of this
suspension and of a 1:10 and 1:100 dilution were plated in
duplicate on wells with 5ml 1.5% methyl cellulose,
followed by 10–12 days of culture at 37 C. For treatment
with ionizing radiation, cells were serially diluted, plated
on methylcellulose, incubated at 37 C for 2h and then
irradiated (137 Cs g-ray source, MDS-Nordion, Canada).
RESULTS
We have recently shown that initiation of the Rad6
pathway by Rad18 is important for SHM (12). To assess
the role of PCNA polyubiquitination in Ig diversiﬁcation,
we wished to inactivate Ubc13 in DT40, using vectors
targeting exons 2–4 (Figure 1A). Inactivation of the ﬁrst
Ubc13 allele in DT40 Cre1 cells could be achieved with
high eﬃciency, but direct inactivation of the second Ubc13
allele proved impossible, as no targeted clones could be
identiﬁed despite repeated attempts. We noticed, though,
that in contrast to the parental Cre1 cells, the Ubc13
+/ 
clones barely converted from the original surface (s)Ig 
conﬁguration due to a frameshift in the expressed Ig light
chain gene to a sIg+ state that is indicative of ongoing Ig
GC (15). We therefore set out to analyse the eﬀects of
Ubc13 heterozygosity on Ig diversiﬁcation in DT40.
To this end, an experimental set comprising two inde-
pendent heterozygous clones and derivatives containing
an Ubc13 over-expression vector was generated. The
genetic status of the cells was conﬁrmed by Southern
Blot (Figure 1B), and Western Blots revealed that Ubc13
expression levels were decreased in heterozygous clones
and restored to or beyond normal levels in the
reconstituted clones, while AID levels remained constant
(Figure 1C).
Table 1. Sequences of oligonucleotides used in this study
Name Sequence
13Ub1 50-gggctcgagtccagcctggccttggctgcttcca-30
13Ub2 50-gggggatcccaaactgtttaacgtaagcactctg-30
13Ub3 50-gggggatccgaataaaagcccagacatcttcagt-30
13Ub4 50-gggactagtaccttcagacacagcactactaccg-30
13Ub8 50-gaagctagcgccaccatggccgggctgcccc-30
13Ub9 50-gggagatctgtcttggcagaacaggagaagtgat-30
13Ub101 50-tagaatcatacagtggtttgggttgga-30
Pu4 50-cagcgcccgaccgaaaggagcgca-30
Bs1 50-cgattgaagaactcattccactcaaatatataccc-30
13Ub201 50-gtgtaagaggacaagcaagatac-30
13Ub202 50-agttgggctaaatgaccttcg-30
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sIg+ cells in multiple independent sIg  subclones (15)
indeed showed a signiﬁcantly decreased Ig GC eﬃciency
in the Ubc13 heterozygous cells that was not evident in the
reconstituted derivatives (Figure 2A and B). To conﬁrm
that Ubc13 levels are critical for eﬃcient Ig GC in DT40,
we polymerase chain reaction (PCR)-ampliﬁed, cloned
and sequenced Ig light chain genes from representative
subclones of the respective genotypes. In the parental
DT40 Cre1 cells, Ig GC events could easily be identiﬁed
in 10 of 24 sequences (Figure 2C). In the heterozygous
cells, however, only one Ig GC event was found in
one clone, while in the other clone a duplication
event and no evidence of Ig GC could be identiﬁed
(Figure 2C). Thus, even moderate interference with
Ubc13 function substantially obstructs the eﬃciency of
Ig GC in DT40.
Interference with HR in DT40 cells may aﬀect the
capacity of the cells to proliferate or survive upon DNA
damage (8,11). Assays of proliferative capacity of the cells
by CFSE labelling revealed no diﬀerences, as generation
times averaged around 11h in all cell types tested
(Supplementary Figure S1A). This indicates that HR
must be functional to an extent allowing the cells to pass
critical events in S/G2 that would otherwise cause cell
death in DT40 (8). Also, sensitivity of the Ubc13
+/ 
cells to cisplatin, mitomycin C and ionizing radiation
was not aﬀected, although Rad18
 /  control cells
behaved as expected (Supplementary Figure S1B–D).
Accordingly, Ubc13 heterozygous cells show normal
proliferation and DNA damage tolerance, but are
characterized by a substantially diminished Ig GC activity.
An impaired function of factors involved in HR, such as
Ubc13, often not only causes a decrease in Ig GC but a
concomitant increase in SHM activity (7). The sequence
analysis shown in Figure 2C, however, indicated no
increased mutagenesis in the variable region. To directly
assess the eﬀect of Ubc13 heterozygosity on SHM, we
inactivated one Ubc13 allele in DT40wV
  cells lacking
the pseudogenes required for Ig GC, which only diversify
their V genes by SHM (16). Curiously, for unknown
reasons, only a heterozygous clone was identiﬁed among
65 clones screened in diﬀerent targeting attempts, and
reconstitution was performed as above. SHM assays
based on subcloning sIg+ cells from each genotype and
determining loss of sIg expression due to deleterious muta-
tions after 2 weeks of culture (Figure 3A) revealed no
signiﬁcant diﬀerence in theUbc13
+/  cloneor the reconsti-
tuted derivative, and neither did sequence analyses
(Figure 3B). These data imply that Ubc13 heterozygosity
impairs homology-mediated repair of AID-induced
lesions without shifting repair balance to more substantial
mutagenesis.
Competition between homology-directed and
TLS-based mutagenic repair mostly occurs when DNA
lesions are encountered during replication (9,10). Ubc13
heterozygosity may not limit its activity to an extent
perturbing the error-free arm of post-replicative repair,
i.e. PCNA polyubiquitination. While excision of AID-
induced uracils by UNG leads to abasic sites that can
give rise to translesion synthesis or homology-based
error-free bypass, they can also be converted to DNA
single- and double-strand breaks by APE1 (17). On these
lesions, repair by HR may compete with NHEJ, and the
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Figure 1. Targeting and reconstitution of Ubc13. (A) Targeting strategy for Ubc13 in DT40 cells. Boxes indicate exons, shaded areas correspond to
coding sequences. Restriction sites and fragment sizes for southern analyses are shown. Bold lines correspond to homologous arms of the targeting
vector. (B) Southern Blot analysis of the DT40 clones used for analysis of Ig GC. 2 independent heterozygous (Ubc13
+/ ) and reconstituted clones
(Ubc13
+/ R) were employed. (C) Western Blot for Ubc13 and AID expression in the clones analysed in (B).
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Figure 2. Ubc13 dosage aﬀects Ig GC. (A) FACS analysis for sIg expression of representative single cell clones of the cells with the indicated
genotypes. Percentage of sIg+ cells are given. (B) Percentage of sIg+ cells in individual single-cell clones of the indicated genotypes. Total numbers
of clones analysed are given below the genotype. Bars represent mean values. Brackets and stars mark statistically signiﬁcant diﬀerences (Student’s
t-test). P-values for Cre1 compared to the reconstituted clones were 0.20367 and 0.07022, respectively. (C) Sequence analysis of the rearranged light
chain gene in representative clones of the cells analysed in (B). The shaded letter marks the original frameshift mutation in DT40Cre1 cells. Brackets
mark deletions. The frequency of the events shown among a total of 24 sequences each, as well as the most likely pseudogene with which recom-
bination occurred, are indicated on the right side.
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mutants implies that double-strand break intermediates
indeed occur during Ig GC (18). We thus reasoned that
in Ubc13 heterozygous cells, NHEJ might limit the
HR-mediated repair of AID-induced damage at DNA
double-strand breaks, and leave no trace in the variable
region sequences due to the intrinsically, mostly error-free
nature of this process.
HR and NHEJ are also the two main competing pro-
cesses determining whether a transfected DNA construct
integrates into the genome at a homologous location or at
random sites, respectively. Indeed, the futility of direct
inactivation attempts of the second Ubc13 allele in our
experiments, which has also been observed in a previous
study, may point to a targeting defect in Ubc13
+/  cells,
as Ubc13
 /  DT40 cells are in principle viable (11). To
obtain insight into the precise nature of the defect in
Ubc13
+/  cells from a diﬀerent perspective, we directly
assessed targeting eﬃciency for the Rad18 and RDM1
loci (12,19). In both cases, a signiﬁcant decrease in
targeted integration was detected in Ubc13
+/  cells
(Table 2, P<0.05 with Fisher’s exact test), indicating
indeed that a decreased Ubc13 activity impairs HR at
the cost of NHEJ in DT40 cells.
DISCUSSION
Most cellular DNA repair pathways are very robust, and
minor changes in the activity of core factors have only
rarely been reported to aﬀect their eﬃciency. Ubc13 is a
highly unique protein in the cell, though, as it is the only
enzyme capable of synthesizing non-canonical ubiquitin
chains via K63 linkages. In models assessing its signalling
functions, gene-dosage eﬀects have already been seen (20).
In the present study, we report that reduction of Ubc13
levels substantially aﬀects Ig GC and targeted DNA inte-
gration. Both reactions require eﬃcient HR, and a key
function of Ubc13 in the initiation of HR has been
revealed before (11). Since HR protects cells from
genetic aberrations, one may infer that under certain con-
ditions even moderate perturbations of Ubc13 regulation
might challenge the genetic integrity of cells. Presently, we
have no evidence that a change in Ubc13 levels alters
PCNA polyubiqintination. A detailed study of the E3
enzymes required for PCNA polyubiquitiation is thus
mandatory.
A primary mode of Ubc13 regulation is control of its
cellular localization. In the cytoplasm of higher
eukaryotes, it performs important functions in signalling
processes in association with Uev1A (21). In the nucleus,
Ubc13 in complex with Mms2 initiates the error-free arm
of the Rad6 pathway by PCNA polyubiquination (9,10)
and also plays a crucial role in the initiation of HR and
other processes at DNA double-strand breaks in associa-
tion with RNF8 and RNF168 (11,22,23). Moreover, the
cellular localization of Ubc13 may be regulated by DNA
damage (24), and in vertebrates Ubc13 regulates and is
regulated by p53 function (25). Thus, the dosage eﬀect
we observe may be a consequence of cross-competition
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Figure 3. Eﬀects of Ubc13 dosage on SHM. (A) Percentage of sIg  cells
in individual single-cell clones of the indicated genotypes. The total
number of clones analysed is given below the respective genotype.
P-values for wV- compared to wV- Ubc13
+/  and wV- Ubc13
+/ R
were 0.56002 and 0.77197, respectively. (B) Sequence analysis of the
rearranged light chain gene in the clones analysed in (A). The relative
fraction of sequences with the indicated number of mutations per
sequence is given. Total numbers of sequences are shown in the insets,
and the mutation frequency is given below the genotype.
Table 2. Targeting eﬃciencies in WT versus Ubc13
+/  clones
Targeted loci Rad18 RDM1
DT40 Cre1 18/45 (40%) 29/100 (29%)
Ubc13
+/  clone 1 5/45 (11%) 18/100 (18%)
Ubc13
+/  clone 2 3/45 (7%) 16/100 (16%)
Nucleic Acids Research, 2010,Vol.38, No. 14 4705of the various cellular pathways that require and aﬀect
Ubc13. Notably, mere assessment or increase of Ubc13
levels in the cell may not predict or aﬀect its activity in
a given process. Accordingly, overall Ubc13 levels do not
diﬀer substantially between cell lines that diﬀer in their
HR capacity (Supplementary Figure S2).
An intriguing observation is the selectivity of the dosage
eﬀects detected in our study. We see compromised Ig GC
and targeted DNA integration, both of which depend on
eﬃcient HR. However, we do not see eﬀects on overall
survival of exogenously caused DNA damage, even for
drugs that require eﬃcient HR for optimal tolerance.
This apparent discrepancy might be based on the induc-
tion of other repair pathways by an exogenously caused
multitude of DNA lesions, which might not occur in case
of low-dose endogenous damage. However, Ubc13
+/ 
cells can even deal with the rare endogenous challenges
during replication, which also require HR for resolution
(8), to an extent that allows the cells to proliferate
normally. Accordingly, diﬀerent repair situations may
simply be diﬀerentially sensitive to changes in Ubc13
levels, potentially based on the relative degree to which
they compete with processes less adequate for proper
resolution of the lesion. Conversely, one may conclude
that an increase of K63-linked ubiquitin conjugation by
other means, such as treatments that increase nuclear
Ubc13 function or by interference with the competing
ubiquitin hydrolase complex Rap80–BRCC36 (26), may
shift the balance in favour of exactly those processes
that are most sensitive to gradual interference with
Ubc13 levels.
In this context, the interference of Ubc13 dosage
changes with the eﬃciency of targeted DNA integration
is of particular interest. Targeting eﬃciencies are excep-
tionally high in DT40 cells (27), and comparable
eﬃciencies in targeted genetic changes in embryonic or
adult stem cells would substantially improve the chances
of minimally obstructive gene therapy. It will thus be
highly interesting to assess targeting eﬃciency in mamma-
lian cells, in which the functionality of enzymes regulating
Ubc13 function or the turnover of K63-linked ubiquitin
chains are modulated.
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